Locomotor activity induced by MK-801 is enhanced in dopamine D3 receptor knockout mice but suppression by dopamine D3/D2 antagonists does not occur through the dopamine D3 receptor

European Journal of Pharmacology

Volumn 627, Issue 1-3, 2010, Pages 167-172

  Yarkov, Alex V ^a   Der, Terry C ^b,c   Joyce, Jeffrey N ^d  

^a Arizona State University   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Dopamine; Glutamate; Locomotion; N methyl d aspartate; Rearing; S33084; Schizophrenia; U99194A

Indexed keywords

2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; DIZOCILPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; N [4 (8 CYANO 1,3A,4,9B TETRAHYDRO 3H BENZOPYRANO[3,4 C]PYRROLE 2YL)BUTYL] (4 PHENYL)BENZAMIDE; S 33804; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; HYPERACTIVITY; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; MUTANT; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN INTERACTION; REARING; WILD TYPE;

ANIMALS; BEHAVIOR, ANIMAL; DIZOCILPINE MALEATE; FEMALE; GENE KNOCKOUT TECHNIQUES; GENOTYPE; LOCOMOTION; MALE; MICE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 73449091114     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.068     Document Type: Article

References (36)

1. Accili D., Fishburn C.S., Drago J., Steiner H., Lachowicz J.E., Park B.H., Gauda E.B., Lee E.J., Cool M.H., Sibley D.R., Gerfen C.R., Westphal H., and Fuchs S. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 1945-1949
2. Audinot V., Newman-Tancredi A., Gobert A., Rivet J.M., Brocco M., Lejeune F., Gluck L., Desposte I., Bervoets K., Dekeyne A., and Millan M.J. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J. Pharmacol. Exp. Ther. 287 (1998) 187-197
3. Banbury Conference on genetic background in mice.1997. Mutant mice and neuroscience: recommendations concerning genetic background. Neuron 19, 755-759.
4. 3 receptor function. Nat. Med. 9 (2003) 762-767
5. 3 knock-out and wild-type mice. Neuropharmacology 38 (1999) 555-565
6. Diana G., and Sagratella S. Different capability of N-methyl-d-aspartate antagonists to affect locomotor/exploratory activity of mice in a computerized on-line open field test. Pharmacol. Biochem. Behav. 48 (1994) 291-295
7. French E.D., Ferkany J., Abreu M., and Levenson S. Effects of competitive N-methyl-d-aspartate antagonists on midbrain dopamine neurons: an electrophysiological and behavioral comparison to phencyclidine. Neuropharmacology 30 (1991) 1039-1046
8. Gyertyan I., and Saghy K. The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 572 (2007) 171-174
9. Irifune M., Shimizu T., Nomoto M., and Fukuda T. Involvement of N-methyl-d-aspartate (NMDA) receptors in noncompetitive NMDA receptor antagonist-induced hyperlocomotion in mice. Pharmacol. Biochem. Behav. 51 (1995) 291-296
10. 3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 90 (2001) 231-259
11. Joyce J.N., and Millan M.J. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov. Today 10 (2005) 917-925
12. 3 receptors. Neuroscience 91 (1999) 911-924
13. Le Foll B., Diaz J., and Sokoloff P. Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice. Life Sci. 76 (2005) 1281-1296
14. 3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology 45 (2003) 174-181
15. Liljequist S., Ossowska K., Grabowska-Anden M., and Anden N.E. Effect of the NMdopamine receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice. Eur. J. Pharmacol. 195 (1991) 55-61
16. Marcus M.M., Mathe J.M., Nomikos G.G., and Svensson T.H. Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens. Neuropharmacology 40 (2001) 482-490
17. Martin P., Waters N., Waters S., Carlsson A., and Carlsson M.L. MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. Eur. J. Pharmacol. 335 (1997) 107-116
18. 3-receptors: II. Functional and behavioural profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 1063-1073.
19. Millan M.J., Gobert A., Newman-Tancredi A., Lejeune F., Cussac D., Rivet J.-M., Audinot V., Dubuffet T., and Lavielle G. S33084, a novel, potent, selective, and competitive antagonist at dopamine D3receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 293 (2000) 1048-1062
20. Millan M.J., Seguin L., Gobert A., Cussac D., and Brocco M. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology (Berl) 174 (2004) 341-357
21. Narayanan S., Willins D., Dalia A., Wallace L., and Uretsky N. Role of dopaminergic mechanisms in the stimulatory effects of MK-801 injected into the ventral tegmental area and the nucleus accumbens. Pharmacol. Biochem. Behav. 54 (1996) 565-573
22. O'Neill M.F., and Shaw G. Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. Psychopharmacology (Berl) 145 (1999) 237-250
23. Pritchard L.M., Logue A.D., Hayes S., Welge J.A., Xu M., Zhang J., Berger S.P., and Richtand N.M. 7-OH-DPAT and PD 128907 selectively activate the D3 dopamine receptor in a novel environment. Neuropsychopharmacology 28 (2003) 100-107
24. Qi C., Zou H., Zhang R., Zhao G., Jin M., and Yu L. Age-related differential sensitivity to MK-801-induced locomotion and stereotypy in C57BL/6 mice. Eur. J. Pharmacol. 580 (2008) 161-168
25. 3 receptor in schizophrenia and in antipsychotic drug actions. Brain Res. Brain Res.Rev. 31 (2000) 277-287
26. Steiner H., Fuchs S., and Accili D. D3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physiol Behav. 63 (1997) 137-141
27. Svensson A., Pileblad E., Carlsson M., Svensson A., Pileblad E., and Carlsson M. A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice. J.Neural Transm.Gen.Sect. 85 (1991) 117
28. Waddington,J.L., Clifford,J.J., McNamara,F.N., Tomiyama,K., Koshikawa,N., Croke,D.T., 2001. The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion ('knockout'). Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 925-964.
29. Waters N., Lofberg L., Haadsma-Svensson S., Svensson K., Sonesson C., and Carlsson A. Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour. J. Neural Transm. Gen. Sect. 98 (1994) 39-55
30. Waters N., Lundgren C., Hansson L.O., and Carlsson M.L. Concurrent locomotor stimulation and decrease in dopamine release in rats and mice after treatment with the competitive NMDA receptor antagonists D-CPPene and CGS 19755. J. Neural Transm. 103 (1996) 117-129
31. Waters N., Svensson K., Haadsma-Svensson S.R., Smith M.W., and Carlsson A. The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J.Neural Transm.Gen.Sect. 94 (1993) 11-19
32. Wolf M.E., White F.J., and Hu X.T. Behavioral sensitization to MK-801 (dizocilpine): neurochemical and electrophysiological correlates in the mesoaccumbens dopamine system. Behav. Pharmacol. 4 (1993) 429-442
33. Wong G.T. Speed congenics: applications for transgenic and knock-out mouse strains. Neuropeptides 36 (2002) 230-236
34. Wong J.Y., Clifford J.J., Massalas J.S., Kinsella A., Waddington J.L., and Drago J. Essential conservation of D1 mutant phenotype at the level of individual topographies of behaviour in mice lacking both D1 and D3 dopamine receptors. Psychopharmacology (Berl) 167 (2003) 167-173
35. Xu M., Koeltzow T.E., Cooper D.C., Tonegawa S., and White F.J. Dopamine D3 receptor mutant and wild-type mice exhibit identical responses to putative D3 receptor-selective agonists and antagonists. Synapse 31 (1999) 210-215
36. 3 receptor knockout mice. Pharmacol. Biochem. Behav. 76 (2003) 551-562